October 28, 2011
"Questioning the Risk Profile of Selegiline Hydrochloride" Poster exhibit presented by Dr.
Emory at Institute on Psychiatric Services Conference, San Francisco.
May 15-18, 2011
“Questioning the Risk Profile of Selegiline Hydrochloride” Poster exhibit presented by Dr.
Emory at American Psychiatric Association Conference, Honolulu.
Psychiatric outcomes for serious mental disorders continue to disappoint. Large studies
published between 2003 and 2007 show less than one third of patients classified with major
depression, bipolar disorder or schizophrenia achieved satisfactory outcomes [1-3].
These studies were supervised by psychiatric experts and represent best psychiatric practice.
The director of the U.S National Institute of Mental Health [NIMH], Thomas Insel, M.D.,
stated “…these trials used evidence-based treatments of well-documented efficacy that were
administered with optimum clinical standards. The results show the significant limitations of
current pharmacological interventions.”
These unsatisfactory results from state of the art psychiatry are indeed troubling, because it
means that many people with mental disorders will continue to live in misery. A likely explanation
for this crisis is that the traditional treatment approach doesn’t directly address the individual
physiology underlying these disorders.
Many medications are available and effective for some people across the array of mental disorders.
Since the goal of medical treatment is to improve individual physiology, a psychiatric medical treatment
should improve individual neurophysiology. The main obstacle to achieving this goal has been the absence
of objective measures to guide medication selection that is likely to be effective for each person.
Mismatches between a prescribed medication and individual neurophysiology explain the current crisis in psychiatry
and call for objective approaches which conform to the medical model.
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Lebowitz BD, Severe
J,
Hsiao JK; Clinical Anti-psychotic Trial of Intervention Effectiveness (CATIE) Investigators. Effectiveness of
antipsychotic
drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-1223
- Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of
findings.
Curr Psychiatry Rep. 2007; 9(6):449-459
- Thase ME. STEP-BD and bipolar depression: what have we learned? Curr Psychiatry Rep. 2007; 9(6):497-503
- Insel, T. R. (2009, February). Translating scientific opportunity into public health impact. Archives of
General Psychiatry,
66(2), 128-133.